FOR YOUR HEAVILY-TREATMENT EXPERIENCED PATIENTS WITH HIV-1 WHOSE ANTIRETROVIRAL REGIMEN IS FAILING
US-TRO-2300023
1
FOR YOUR HEAVILY-TREATMENT EXPERIENCED PATIENTS WITH HIV-1 WHOSE ANTIRETROVIRAL REGIMEN IS FAILING
1
TROGARZO®: THE FIRST AND ONLY CD4-DIRECTED MONOCLONAL ANTIBODY FOR HIV-11
Active against ARV-resistant strains with no cross-resistance to other ARVs1
Active against ARV-resistant strains with no cross-resistance to other ARVs1
1
IMPORANT SAFETY INFORMATIONIndicationTROGARZO® (ibalizumab-uiyk), in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.ContraindicationsTROGARZO® is contraindicated in patients with a prior hypersensitivity reaction to TROGARZO® or any components of the product.Warnings and PrecautionsHypersensitivity Including Infusion-Related and Anaphylactic Reactions Hypersensitivity reactions including infusion- related reactions and anaphylactic reactions have been reported following infusion of TROGARZO® during post-approval use. Symptoms may include dyspnea, angioedema, wheezing, chest pain, chest tightness, cough, hot flush, nausea, and vomiting. If signs and symptoms of an anaphylactic or other clinically significant hypersensitivity reaction occur, immediately discontinue administration of TROGARZO® and initiate appropriate treatment.Immune Reconstitution Inflammatory Syndrome Immune Reconstitution Inflammatory Syndrome (IRIS) has been reported in one patient treated with TROGARZO® in combination with other antiretrovirals. During the initial phase of combination antiretroviral therapies, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections, which may necessitate further evaluation and treatment.Embryo-Fetal Toxicity Based on animal data, TROGARZO® may cause reversible immunosuppression (CD4+ T cell and B cell lymphocytopenia) in infants born to mothers exposed to TROGARZO® during pregnancy. Immune phenotyping of the peripheral blood and expert consultation are recommended to provide guidance regarding monitoring and management of exposed infants based on the degree of immunosuppression observed. The safety of administering live or live attenuated vaccines in exposed infants is unknown.Adverse ReactionsThe most common adverse reactions (all Grades) seen in clinical trial experience, reported in at least 5% of subjects receiving TROGARZO® were diarrhea (8%), dizziness (8%), nausea (5%) and rash (5%).Most (90%) of the adverse reactions reported were mild or moderate in severity. Two subjects experienced severe adverse reactions: one subject had a severe rash and one subject developed IRIS manifested as an exacerbation of progressive multifocal leukoencephalopathy.Use in Specific PopulationsPregnancy: No adequate human data are available to establish whether or not TROGARZO® poses a risk to pregnancy outcomes. Monoclonal antibodies, such as ibalizumab-uiyk, are transported across the placenta as pregnancy progresses; therefore, ibalizumab-uiyk has the potential to be transmitted from the mother to the developing fetus.Lactation: No data are available regarding the presence of TROGARZO® in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for HIV-1 transmission, instruct mothers not to breastfeed if they are receiving TROGARZO®.To report SUSPECTED ADVERSE REACTIONS, contact THERA patient support® at 1-833-23THERA (1-833-238-4372) or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch/.ARV = antiretroviral; HIV = human immunodeficiency virus.Reference:1. TROGARZO® Prescribing Information. Theratechnologies Inc. October 2022.TROGARZO® is a registered trademark of TaiMed Biologics Inc., under license to Theratechnologies Inc.© 2023 Theratechnologies Inc. All rights reserved.US-TRO-2300023
SEE THE TROGARZO® DIFFERENCE
SEE THE TROGARZO® DIFFERENCE